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spirating and Filtering
therothrombotic Debris
uring Percutaneous
oronary Intervention*
ric R. Bates, MD, FACC
nn Arbor, Michigan
he coronary “no-reflow” phenomenon can occur during
eperfusion of an infarct artery or after percutaneous coro-
ary intervention (PCI) (1). It represents inadequate myo-
ardial perfusion despite epicardial coronary artery patency
nd can be caused by reperfusion injury, embolization of
therosclerotic or thrombotic debris, or ischemia-induced
icrovascular damage from endothelial cell injury, leuko-
yte plugging of capillaries, myocardial cell edema, free
xygen radical generation, and microvascular spasm. Persis-
ent no-reflow is associated with a high incidence of
yocardial infarction (MI) and the risks of congestive heart
ailure and death.
See pages 248 and 258
Multiple pharmacological and device therapies have been
eveloped in an attempt to protect the myocyte from
icrovascular injury. Thrombectomy and embolic protec-
ion devices (EPDs) are used to reduce the risk of distal
therothrombotic embolization during primary PCI and
aphenous vein graft (SVG) PCI. Although these devices
ncrease procedure time and complexity, radiation exposure,
nd cost, they would become routine adjunctive therapy
ith primary PCI and SVG PCI if they could be shown to
educe the risk of MI, congestive heart failure, and death.
yocyte Protection by Device Therapy
hrombectomy devices. Thrombectomy devices avoid the
eed to initially cross the target lesion with a device and
educe the thrombus burden before PCI. Thrombectomy
atheter systems that mechanically disrupt and aspirate
ntravascular thrombus have proven disappointing and in-
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC or the American College
f Cardiology.w
From the Division of Cardiovascular Diseases, Department of Internal Medicine,
niversity of Michigan, Ann Arbor, Michigan.luded the AngioJet rheolytic system (Possis Medical Inc.,
inneapolis, Minnesota), the X-Sizer mechanical throm-
ectomy system (eV3, Inc. Plymouth, Minnesota), and the
inspiration system (Kerberos Proximal Solutions, Cuper-
ino, California). More promising results have been seen
ith simple thrombus aspiration catheters. The Rescue PT
ystem (Boston Scientific, Maple Grove, Minnesota) and
he thrombus vacuum aspiration catheter (TVAC) (Nipro,
saka, Japan) are aspiration catheters that employ a prox-
mal vacuum pump with a collection bottle. Manual throm-
us aspiration with a syringe can be performed through a
uide catheter or the central lumen of the Export
Medtronic Vascular, Santa Rosa, California), Diver CE
eV3), and Pronto (Vascular Solutions, Inc., Minneapolis,
innesota) aspiration catheters. Thrombus aspiration can
elp define the stenosis and facilitate a strategy of direct
tenting during primary PCI, but catheter lumen size might
imit aspiration of large thrombus mass. Although throm-
ectomy catheters can decrease thrombus burden, they do
ot protect against distal embolization during the subse-
uent PCI procedure.
PDs. There are two types of EPDs: filter devices and
cclusion-aspiration devices. Distal embolic filter devices
aintain distal perfusion and allow injection of contrast
edium during PCI while trapping most particulate debris.
imitations include need for a suitable landing zone, fre-
uent need to predilate the lesion to allow passage of the
lter device, embolization during passage of the device distal
o the lesion, failure to prevent embolization into side
ranches proximal to the filter, possible trauma to the vessel,
nd failure to trap particles 100 m. Embolic filters
nclude the FilterWire-EZ (Boston Scientific), the SpideRX
rotection device (eV3), and the Interceptor Plus Coronary
ilter System (Medtronic Vascular).
Proximal and distal occlusion-aspiration devices suspend
ntegrade flow during the intervention. The stagnant col-
mn of blood containing particulate debris and humoral
ediators is aspirated before relief of distal occlusion and
estoration of flow. Disadvantages include poor vessel opaci-
cation during the procedure and distal ischemia while
cclusion is maintained. The Proxis embolic protection
ystem (St. Jude Medical, St. Paul, Minnesota) is a proximal
cclusion device. It protects all distal side branches, but the
equirement of a proximal landing zone precludes its use in
ery proximal lesions. Distal occlusion devices include the
urcuSurge GuardWire (Medtronic Vascular) and the
riActive system (Kensey Nash, Exton, Pennsylvania).
hey share the limitations of the distal filter devices noted
reviously, with the exception of trapping smaller particles.
rimary PCI
espite successful epicardial coronary artery reperfusion
ith primary PCI, impaired myocardial reperfusion persists
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266n 30% of patients and is suggested by slow coronary blood
ow, abnormal myocardial blush grade, or persistent ST-
egment elevation. Smaller studies with thrombectomy
atheters and EPDs have shown encouraging results in
mproving microvascular reperfusion (better coronary flow,
yocardial blush grade, and ST-segment resolution) after
rimary PCI (2,3), but larger studies (200 patients) have
ot (4,5). Despite frequent recovery of atherothrombotic
ebris and a decrease in angiographic embolization rates,
here has been no evidence to suggest that these interven-
ions reduce myocardial infarct size, reinfarction, or mortal-
ty (2,3).
Besides the previously described limitations of the de-
ices, limitations of the trials include small sample sizes,
ean ischemic times 4 h, and the inclusion of low-risk
esions (patent arteries, circumflex and branch arteries) and
ow-risk patients (30-day mortality 3%). Therefore, it was
ith great interest and some surprise that the TAPAS
Thrombus Aspiration during Percutaneous Coronary In-
ervention in Acute Myocardial Infarction Study) trial
ecently reported improved reperfusion and clinical out-
omes with a strategy of manual thrombus aspiration
hrough the Export catheter and direct stenting irrespective
f clinical and angiographic characteristics (6,7). Impor-
antly, the TAPAS trial was a single-center study conducted
y superb interventionalists in 1,071 patients, and the mean
ime-to-treatment of 3 h was a least 1 h faster than in
revious studies. In this issue of JACC: Cardiovascular
nterventions, the TAPAS trial investigators report a cohort
tudy with 2 manual thrombus aspiration catheters: the
iver catheter (internal lumen 0.062 inches) and the Export
atheter (internal lumen 0.041 inches) (8). There were no
ifferences in successful thrombus aspiration, Thrombolysis
n Myocardial Infarction flow, myocardial blush grade,
T-segment elevation resolution, retrieved particle size, or
linical outcomes despite the difference in catheter lumen
iameter. The question remains whether the potential
enefit with this aspiration strategy is due to thrombectomy
lone or thrombectomy plus direct stenting (6,7,9).
VG PCI
ompared with coronary artery interventions, SVG PCI is
ssociated with increased risk for morbidity and mortality.
he major factor is distal embolization of atherothrombotic
ebris resulting in no-reflow and periprocedural MI. Risk
an be estimated by angiographic estimates of plaque
olume and SVG degeneration (10) and by the presence of
hrombus. A pooled analysis of 5 randomized clinical trials
emonstrated no reduction in risk with glycoprotein (GP)
Ib/IIIa inhibitors administered during SVG PCI (11).
The American College of Cardiology/American Heart
ssociation/Society for Cardiovascular Angiography andnterventions 2005 guideline update for PCI gives a class Ib mecommendation for the use of EPDs during SVG PCI
hen technically feasible (12). Likewise, the European
ociety of Cardiology Guidelines for PCI gives EPDs a
lass Ia recommendation for SVG PCI (13). Interestingly, a
eview of the published reports reveals only 1 randomized
ontrolled trial with 801 patients that enrolled 8 years ago.
he SAFER (Saphenous vein graft Angioplasty Free of
mboli Randomized) trial demonstrated a reduction in the
omposite end point of death, MI, emergency bypass
urgery, or target lesion revascularization at 30 days with the
uardWire device versus conventional guidewire use (14).
ubsequent EPDs have only been tested against an active
ontrol group in noninferiority comparisons (15-17). As
ith GP IIb/IIIa inhibitor therapy in native coronary
nterventions, the major benefit has been in decreasing
eriprocedural MI measured by biomarker release; no im-
act on 30-day Q-wave MI or mortality rates has been
uggested, and there are no data on long-term survival.
lthough all would agree that it is desirable to prevent
eriprocedural MI, the relationship between periprocedural
I and long-term prognosis might be more by association
han causality (18). Because patients undergoing coronary
rtery bypass graft surgery often have a large atherosclerotic
urden, decreased ventricular function, and significant co-
orbidities, there are many other factors that contribute to
heir prognosis, with the strong possibility that emboliza-
ion during SVG PCI is a surrogate marker of increased
verall risk.
In this issue of JACC: Cardiovascular Interventions, the
MEthyst (Assessment of the Medtronic AVE Interceptor
aphenous Vein Graft Filter System) study investigators
eport the successful results of another noninferiority com-
arison trial that will probably lead to Food and Drug
dministration approval of another EPD (19,20). How-
ver, before we consider using these devices routinely, it is
mportant to recognize that anatomic exclusions might be
resent in one-half the cases and EPDs are currently used in
nly one-quarter of SVG PCI (21). One explanation for the
ifference between eligibility and use is that many SVGs
erfuse branch arteries or small areas of myocardium, so the
nterventionalist might be choosing the faster, easier proce-
ure. Also, only an internal mammary artery graft to the left
nterior descending artery has been shown to improve
ong-term prognosis, so optimal medical therapy is another
reatment option for severely degenerated SVGs.
onclusions
t the present time, routine use of mechanical protection
evices during primary PCI cannot be recommended. How-
ver, manual thrombus aspiration is an attractive concept
hat is easy, fast, and deserves further investigation in
ulticenter trials focusing on patients with large infarct
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267rteries occluded by thrombus who present early for primary
CI.
Selective use of EPDs in SVG PCI is reasonable, but
vent rates after SVG PCI have decreased in recent years
19). Better patient selection, more frequent pretreatment
ith statins and clopidogrel, more aggressive use of intra-
raft vasodilator administration before and after PCI, better
tents, and adoption of a direct stenting strategy with 1
alloon inflation and only 1 stent suggests to me that
nough equipoise exists to ethically support a randomized
linical trial of EPD versus conventional guidewire use in
he current interventional cardiology era.
Although there are no randomized trials proving benefit
or EDPs with carotid stenting, it seems intuitively obvious
hat any intervention that prevents embolism to the brain
hould be employed. However, the heart is a more forgiving
rgan, and the importance of distal embolization into a
-h-old infarct zone or down an SVG into a distal branch
rtery is less clear. Only 1 positive randomized trial sup-
orting reduction in major adverse cardiac events exists for
ach potential indication. One is a single-center study, and
he other is 8 years old. I believe more randomized,
ontrolled clinical trial data are needed before we add
outine aspiration thrombectomy to primary PCI or routine
PDs to SVG PCI.
eprint requests and correspondence: Dr. Eric R. Bates, CVC
ardiovascular Medicine, 1500 East Medical Center Drive, Ann
rbor, Michigan 48109-5869. E-mail:ebates@umich.edu.
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